Publication|Articles|November 12, 2025
Supplements and Featured Publications
- Clinical and Economic Considerations for Nivolumab-Based Therapy for Resectable Non–Small Cell Lung Cancer
Clinical and Economic Considerations for Nivolumab-Based Therapy for Resectable Non–Small Cell Lung Cancer
Listen
0:00 / 0:00
Advertisement
This clinical brief is sponsored by Bristol Myers Squibb and is intended for payers, formulary committees, or other similar individuals or entities with knowledge and expertise in the area of health care economic analysis carrying out responsibilities for the selection of drugs for coverage, reimbursement, or other population-based health care management.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cefdinir Nearly Doubles Outpatient Uncomplicated UTI Treatment Failure Compared With Cephalexin
2
Stronger Carer-Child Bonds Don’t Predict Later Mental Health
3
Five Ways AI Is Transforming Cancer Care—and Companies That Are Making It Happen
4
Intermountain Spans Time Zones, Cultures to Bring Oncology Care to Alaska
5











































